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Background: Some studies have evaluated vaccine effectiveness in preventing outpatient influenza while others
have analysed its effectiveness in preventing hospitalizations. This study evaluates the effectiveness of the trivalent
influenza vaccine in preventing outpatient illness and hospitalizations from laboratory-confirmed influenza in the
2010–2011 season.
Methods: We conducted a nested case–control study in the population covered by the general practitioner
sentinel network for influenza surveillance in Navarre, Spain. Patients with influenza-like illness in hospitals and
primary health care were swabbed for influenza testing. Influenza vaccination status and other covariates were
obtained from health care databases. Using logistic regression, the vaccination status of laboratory-confirmed
influenza cases was compared with that of test-negative controls, adjusting for age, sex, comorbidity, outpatient
visits in the previous 12 months, health care setting, time between symptom onset and swabbing, period and A
(H1N1)pdm09 vaccination. Effectiveness was calculated as (1-odds ratio)x100.
Results: The 303 confirmed influenza cases (88% for A(H1N1)pdm09 influenza) were compared with the 286
influenza test-negative controls. The percentage of persons vaccinated against influenza was 4.3% and 15.7%,
respectively (p<0.001). The adjusted estimate of effectiveness was 67% (95% CI: 24%, 86%) for all patients and 64%
(95% CI: 8%, 86%) in those with an indication for vaccination (persons age 60 or older or with major chronic
conditions). Having received both the 2010–2011 seasonal influenza vaccine and the 2009–2010 pandemic
influenza vaccine provided 87% protection (95% CI: 30%, 98%) as compared to those not vaccinated.
Conclusion: The 2010–2011 seasonal influenza vaccine had a moderate protective effect in preventing laboratory-
confirmed influenza.
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Influenza is an important health problem that can lead to
serious complications in persons with risk factors [1,2].
Annual vaccination is the primary measure for preventing
influenza and its complications [3]. Because the influenza
vaccine composition is adapted each season to the viruses
in circulation, its effectiveness varies [4]. In the absence of* Correspondence: imartinba@navarra.es
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distribution, and reproduction in any mediumclinical trials, observational studies are the main way to
evaluate vaccine effectiveness in each season, however, a
number of biases affecting comparability between vacci-
nated and unvaccinated persons must be overcome [5-8].
Studies looking at poorly specified outcomes tend to
underestimate the effect of the intervention [6], whereas
those that analyze virologically-confirmed cases reduce
this problem [4,9]. A design that compares confirmed in-
fluenza cases with test-negative controls tends to improve
the comparability and is easy to carry out, thus this type
of study has come to be widely used [4,9-14]. Severalentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Martínez-Baz et al. BMC Public Health 2013, 13:191 Page 2 of 8
http://www.biomedcentral.com/1471-2458/13/191studies have applied this methodology in patients recruited
in primary care, which provides an estimate of the effect of
the vaccine in preventing mild cases [9-12]. Other studies
have analyzed hospitalized patients, which provides an esti-
mate of vaccine effectiveness in preventing serious forms
of illness [13,14].
This study uses a test-negative case–control design
nested in a population-based cohort to evaluate the
effectiveness of the influenza vaccine in the 2010–2011
season in preventing laboratory-confirmed influenza, in-
cluding both outpatient and hospitalized patients.
Methods
Study population
The present study was based on electronic clinical
records in the region of Navarre, Spain. The Navarre
Ethical Committee for Medical Research approved the
study protocol.
The Navarre Health Service provides health care, free
at point of service, to 97% of the population of the
region. The clinical records have been computerized
since 2000, and include those from primary care,
hospital admissions and laboratory test results.
In Navarre the trivalent inactivated non-adjuvanted
vaccine was recommended and offered free of charge to
people aged 60 or over and to those with major chronic
conditions. Other people can also be vaccinated if they
pay for the vaccine. In the 2010–2011 season the vac-
cine included strains A/California/07/2009(H1N1)-like,
A/Perth/16/2009(H3N2)-like and B/Brisbane/60/2008-like
virus [15]. Monovalent influenza A(H1N1)2009 vaccine
[16] had been administered to individuals with major
chronic conditions in the 2009–2010 season. Precise in-
structions for registering each dose were given to all
vaccination points [17].
Influenza surveillance was based on automatic reporting
from the electronic medical records of all cases of
influenza-like illness (ILI) from all primary health care
centers and hospitals. In both settings ILI was considered
to be the sudden onset of any general symptom (fever or
feverishness, malaise, headache or myalgia) in addition to
any respiratory symptom (cough, sore throat or shortness
of breath). A sentinel network of 74 primary care physi-
cians and pediatricians were asked to take swabs, after
obtaining verbal informed consent, from all their patients
diagnosed with ILI whose symptoms had begun preferably
less than 5 days previously. An agreed protocol of care for
influenza cases was applied in hospitals, which specified
early detection and nasopharyngeal swabbing of all hospi-
talized patients with ILI. Swabs were processed by
real-time reverse transcription polymerase chain reac-
tion (RT-PCR) assay in two laboratories in the region,
and positive samples were characterized for influenza
A (H1 and H3), A(H1N1)pdm09 and B virus. Two positiveswabs for each week were sent to the national influenza
reference laboratory for genotyping.
Study design and statistical analysis
We carried out a nested case–control study based on elec-
tronic clinical records. The study population included all
persons over 6 months of age who received medical care
from physicians in the sentinel network. Health care
workers and institutionalized persons were excluded. The
study population included 97,597 persons. The study
began the first week in which influenza virus was detected
following the first 15 days of the vaccination campaign
and ended the week preceding two consecutive weeks in
which none of the ILI patients recruited tested positive for
influenza. Accordingly, the study covered the period from
week 43 of 2010 to week 12 of 2011.
The cases were all patients diagnosed with influenza
syndrome in primary care or in hospitals who were con-
firmed for influenza virus. The controls were patients
with influenza syndrome who were negative for influ-
enza virus.
The vaccination status for the trivalent 2010–2011 sea-
sonal influenza vaccine and monovalent A(H1N1)pdm09
influenza vaccine was obtained from the online regional
vaccination register [18]. Subjects were considered to be
protected 14 days after vaccine administration.
From the electronic health care records we obtained
the following baseline characteristics: sex, age, district of
residence, major chronic conditions and primary health
care visits in the previous 12 months. Logistic regression
techniques were used to calculate crude odds ratios
(ORs), and ORs adjusted for the mentioned variables,
for health care setting, for swabbing within 4 days of
symptom onset and for date of visit grouped into 4-
week periods. When necessary, exact logistic regression
was used.
The effects of the 2010–2011 seasonal vaccine and the
monovalent A(H1N1)pdm09 vaccine were evaluated as
independent variables in one model, and as a combined
variable (unvaccinated, only seasonal vaccine, only pan-
demic vaccine, or both vaccines) in a different model.
Specific analyses were made under different situations:
comparing cases of each type of influenza with negative
controls, including only patients in whom influenza
vaccination was indicated because they were 60 years of
age or older or had some major chronic condition, consid-
ering only patients in primary care or only hospitalized
patients, and including only swabs taken in the first 4 days
after symptom onset. All adjusted analyses included both
influenza vaccines, except the analysis of influenza B, since
the pandemic vaccine did not include this virus. All
relevant covariates were maintained in the models for
each specific analysis. Percentages were compared by χ2.
Vaccine effectiveness was estimated as (1-OR)x100.
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Description of cases and controls
The weekly number of swabbed patients followed the pat-
tern of ILI incidence in the population (Figure 1). During
the study period, 589 ILI patients were swabbed, 530 in
primary health care and 59 in hospitals. Some 51.4% (303)
were confirmed for influenza virus: 267 for influenza A
(H1N1)pdm2009, 3 for influenza A(H3N2) and 33 for in-
fluenza B. Thirty-one of these strains were characterized
in the national influenza reference laboratory: 23 were
A/California/07/2009(H1N1), 1 was A/England/142/2010
(H1N1), 2 were A/HongKong/2121/2010(H3N2), 1 was B/
Bangladesh/3333/2007(Yamagata) and 4 were B/Brisbane/
60/2008(Victoria).
Compared with confirmed cases of influenza, test-
negative controls had a higher proportion of persons who
were age 65 or over, who had consulted a physician five or
more times in the last year, who had more than one major
chronic condition, who were diagnosed between week
51 of 2010 and 2 of 2011, and who were treated in the
hospital. A smaller proportion of cases than controls had
been vaccinated against influenza A(H1N1)pdm2009, and
this was also true for the 2010–2011 seasonal vaccine.
There were no differences between cases and controls by
sex, residence or swabbing within 4 days of symptom
onset. All patients were swabbed within 8 days of
symptom onset (Table 1).
Effectiveness of the 2010–2011 seasonal influenza vaccine
Compared with test-negative controls, a smaller propor-

























Incidence of influenza-like illness
2010
Study period
Figure 1 Number of test-negative controls and influenza cases, and in2010–2011 seasonal influenza vaccine (OR: 0.24; 95% CI:
0.13; 0.46; p<0.001). In the analysis adjusted for age, sex,
major chronic conditions, outpatient visits in the previ-
ous year, swabbing within 4 days of symptom onset,
health care setting, period and previous monovalent
pandemic vaccination, the effectiveness of the seasonal
vaccine was 67% (95% CI: 24%, 86%; p=0.009). In the
analysis restricted to swabs taken within the first 4 days
after symptom onset, the estimate was 65% (95% CI:
16%, 85%; p=0.018).
The effectiveness of the 2010–2011 influenza vaccine
against cases of influenza A(H1N1)pdm2009 was 61%
(95% CI: 9%, 83%; p=0.030). Using exact logistic regres-
sion techniques, influenza vaccine effectiveness against
influenza B virus was estimated as 93% (95% CI: 36%,
100%; p=0.017).
In the analysis restricted to persons in whom the vac-
cine was indicated, the effectiveness was 64% (95% CI:
8%, 86%; p=0.034).
In the analysis that included only patients diag-
nosed in primary care, vaccine effectiveness rose to 68%
(95% CI: 17%, 87%; p=0.019). Estimates of the vaccine
effectiveness were similar for people aged less than 50
(73%; 95% CI: -21%, 94%; p=0.086) and those aged 50 or
over (69%; 95% CI: 0%, 91%; p=0.050) (Table 2).
Effect of the monovalent A(H1N1)pdm09 vaccine received
in the previous season
A smaller proportion of influenza cases than controls had
received the pandemic vaccine (2.0% and 9.1%, respect-
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n (%) n (%) p-value
Total 303 (100) 286 (100)
Age groups (years) 0.004
< 5 10 (3.3) 9 (3.1)
5 - 14 38 (12.4) 19 (6.6)
15 - 44 174 (57.4) 151 (52.8)
45 - 64 65 (21.5) 69 (24.1)
65 - 79 13 (4.3) 26 (9.1)
≥ 80 3 (1.0) 12 (4.2)
Sex 0.387
Male 146 (48.2) 148 (51.7)
Female 157 (51.8) 138 (48.3)
Residence 0.943
Rural 43 (14.2) 40 (14.0)




0 232 (76.5) 199 (69.6)
1 59 (19.5) 56 (19.6)
> 1 12 (4.0) 31 (10.8)
Outpatient visits in the
previous year
0.047
0 53 (17.5) 33 (11.5)
1 to 4 134 (44.2) 120 (42.0)
> 4 116 (38.3) 133 (46.5)
Health care setting <0.001
Primary health care 290 (95.7) 240 (83.9)
Hospital 13 (4.3) 46 (16.1)
Period <0.001
Week 43 to 46/2010 5 (1.7) 40 (14.0)
Week 47 to 50/2010 6 (1.9) 18 (6.3)
Week 51/2010 to 2/
2011
192 (63.4) 101 (35.3)
Week 3 to 6/2011 81 (26.7) 95 (33.2)





≤4 days 297 (98.0) 274 (95.8)




No 297 (98.0) 260 (90.9)
Yes 6 (2.0) 26 (9.1)




No 290 (95.7) 241 (84.3)
Yes 13 (4.3) 45 (15.7)
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seasonal vaccination, the protective effect of the pandemic
vaccine was partially diluted and did not reach statistical
significance (Table 2).
Table 3 shows the specific effectiveness of both
vaccines as a combined variable (unvaccinated, only
seasonal vaccine, only pandemic vaccine, or both
vaccines). In persons who had not received the pan-
demic vaccine, the effect of the 2010–2011 seasonal
vaccine in preventing confirmed influenza cases was
64% (95% CI: 14%, 85%; p=0.022), whereas having
received both vaccines provided 87% (95% CI: 30%, 98%;
p=0.017) protection against laboratory-confirmed influ-
enza in the 2010–2011 season. The interaction term
between the two vaccines was not statistically significant
(p=0.502). Estimates of vaccine effectiveness were similar
both in the analysis restricted to cases of influenza
A(H1N1)pdm2009 and in the analysis of the target
population for vaccination.Discussion
The results of this study show a moderate protective
effect of the 2010–2011 seasonal influenza vaccine in
preventing laboratory-confirmed influenza during the
2010–2011 seasonal period in Navarre, during which
there was a good match between the circulating viruses
and those included in the vaccine. The vaccine was
shown to be effective against the two main viruses circu-
lating in the region during the season: A(H1N1)pdm09
virus and B virus. Unlike other studies, ours included both
outpatient and hospital cases systematically recruited in a
previously defined population.
The effectiveness we found is similar or slightly higher
than that described in other studies made in outpatients
in the 2010–2011 season, with small differences that
could be explained by the pattern of viruses circulating
in each place [10,11].
The results concerning a possible residual effect of
monovalent influenza A(H1N1)pdm09 vaccination in
the previous season were not conclusive. As in other
studies, a greater protective effect was observed with
both vaccines than with seasonal vaccine alone [11,12],
but in our study this difference was not statistically
significant. Influenza A(H1N1)pdm09 virus was found in
88% of the laboratory-confirmed influenza cases and was
Table 2 Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in the 2010–2011 season in
Navarre, Spain
Cases/controls Crude vaccine effectiveness,
% (95% CI)





No 297/260 Ref. Ref.
Yes 6/26 80 (50; 92) <0.001 45 (−68; 82) a 0.297
Seasonal vaccine 2010-2011
No 290/241 Ref. Ref.
Yes 13/45 76 (54; 87) <0.001 67 (24; 86) a 0.009
Patients swabbed within 4 days of
symptom onset
Pandemic vaccine 2009-2010
No 292/250 Ref. Ref.
Yes 6/25 79 (49; 92) 0.001 44 (−71; 82) a 0.309
Seasonal vaccine 2010-2011
No 286/235 Ref. Ref.
Yes 12/40 75 (52; 87) <0.001 65 (16; 85) a 0.018
Influenza A(H1N1)pdm09 cases vs.
controls
Pandemic vaccine 2009-2010
No 262/260 Ref. Ref.
Yes 5/26 81 (49; 93) <0.001 60 (−30; 87) a 0.129
Seasonal vaccine 2010-2011
No 254/241 Ref. Ref.
Yes 13/45 73 (48; 86) <0.001 61 (9; 83) a 0.030
Influenza B cases vs. controls
Seasonal vaccine 2010-2011
No 33/241 Ref. Ref.
Yes 0/45 89 (33; 100)c 0.010 93 (36; 100) c,d 0.017
Subjects with indication for seasonal
vaccination b
Pandemic vaccine 2009-2010
No 82/85 Ref. Ref.
Yes 6/21 70 (24; 89) 0.013 28 (−147; 79) a 0.599
Seasonal vaccine 2010-2011
No 76/69 Ref. Ref.
Yes 12/37 71 (39; 86) 0.001 64 (8; 86) a 0.034
Primary health care patients
Pandemic vaccine 2009-2010
No 286/227 Ref. Ref.
Yes 4/13 76 (24; 92) 0.015 56 (−70; 89) e 0.231
Seasonal vaccine 2010-2011
No 280/216 Ref. Ref.
Yes 10/24 68 (31; 75) 0.003 68 (17; 87) e 0.019
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No 11/33 Ref. Ref.
Yes 2/13 54 (−137; 91) c 0.355 8 (−967; 94) c,e 1.000
Seasonal vaccine 2010-2011
No 10/25 Ref. Ref.
Yes 3/21 64 (−47; 91) c 0.154 61 (−316; 98) c,e 0.677
Subjects aged less than 50 years
Pandemic vaccine 2009-2010
No 246/191 Ref. Ref.
Yes 2/6 74 (−30; 95) 0.100 60 (−65; 94) a 0.341
Seasonal vaccine 2010-2011
No 245/188 Ref. Ref.
Yes 3/9 75 (4; 93) 0.043 73 (−21; 94) a 0.086
Subjects aged 50 years or older
Pandemic vaccine 2009-2010
No 51/69 Ref. Ref.
Yes 4/20 73 (26; 91) 0.024 47 (−133; 88) a 0.401
Seasonal vaccine 2010-2011
No 45/53 Ref. Ref.
Yes 10/36 67 (27; 85) 0.007 69 (0; 91) a 0.050
CI confidence interval.
a Estimates obtained by a logistic regression model including 2010–2011 seasonal and monovalent A(H1N1)pdm09 influenza vaccination, and adjusted for sex,
age, major chronic conditions, outpatient visits in the previous year, swabbing within 4 days of symptom onset, health care setting and period.
b Indication for vaccination includes people age ≥60 years old and people with major chronic conditions.
c Estimates obtained by exact logistic regression.
d Estimates obtained by a logistic regression model including 2010–2011 seasonal influenza vaccination, and adjusted for sex, age, major chronic conditions,
outpatient visits in the previous year, swabbing within 4 days of symptom onset, health care setting and period.
e Estimates obtained by a logistic regression model including 2010–2011 seasonal and monovalent A(H1N1)pdm09 influenza vaccination, and adjusted for sex,
age, major chronic conditions, outpatient visits in the previous year, swabbing within 4 days of symptom onset and period.
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with which most of the population had had no previous
contact, dual vaccination may have helped to achieve a
better immune response [19-21]. However, this finding
could be due to biases since previous receipt of the
pandemic vaccine may be an indicator of health-seeking
behaviours.
The seasonal influenza vaccine had a high effectiveness
against influenza B. Most characterizations of influenza B
viruses were similar to B/Brisbane/60/2008(Victoria),
which was the strain included in the seasonal vaccine [15].
Longer time between symptom onset and swabbing
has been associated with reduced sensitivity in virus
detection, which could underestimate vaccine effective-
ness [6]. We controlled for this effect mainly in the
design of our study, since 97% of the swabs were taken
within the first 4 days after symptom onset. Moreover,
all analyses were adjusted for this variable and the ana-
lysis was repeated after eliminating the cases swabbedafter the first 4 days, with no relevant changes found in
the estimate of vaccine effectiveness.
In Navarre, the vaccine was indicated for all persons aged
60 or over and for persons with major chronic diseases that
increase the risk of influenza complications. Restricting the
analysis to this population group, the effectiveness of the
influenza vaccine was similar, despite the fact that factors
such as advanced age or some immunodepression may be
more common among people with major chronic condi-
tions, which would explain poor response to the vaccine.
Primary care patients made up the bulk of subjects in
our study and, when the analysis was limited to these
patients, the effectiveness of the vaccine was maintained.
The number of cases treated in hospitals was small,
which did not allow us to obtain a statistically significant
estimate of the effect of the vaccine in preventing
hospitalized cases. Nevertheless, a study conducted
in the same region and season to evaluate vaccine effect-
iveness in preventing hospitalizations with confirmed
Table 3 Estimates of the effect of the 2010–2011 seasonal influenza vaccine and monovalent influenza A(H1N1)pdm09
vaccine in preventing laboratory-confirmed influenza, Navarre, Spain 2010–2011
Case/control Crude vaccine effectiveness,
% (95% CI) a
P-value Adjusted vaccine effectiveness,
% (95% CI) b
P-value
All swabbed patients
Seasonal and pandemic vaccines 2 / 19 91 (63; 98) 0.001 87 (30; 98) 0.017
Only seasonal vaccine 11 / 26 65 (28; 83) 0.004 64 (14; 85) 0.022
Only pandemic vaccine 4 / 7 53 (−62; 86) 0.230 21 (−252; 82) 0.755
Unvaccinated 286 / 234 Ref. Ref.
Influenza A(H1N1)pdm09 cases vs.
controls
Seasonal and pandemic vaccines 2 / 19 91 (57; 98) 0.002 86 (25; 97) 0.022
Only seasonal vaccine 11 / 26 61 (18; 81) 0.012 60 (2; 83) 0.044
Only pandemic vaccine 3 / 7 60 (−56; 90) 0.187 53 (−132; 91) 0.351
Unvaccinated 251 / 234 Ref. Ref.
Subjects with indication for
seasonal vaccination
Seasonal and pandemic vaccines 2 / 16 89 (50; 97) 0.004 81 (−9; 97) 0.062
Only seasonal vaccine 10 / 21 58 (3; 81) 0.041 50 (−38; 82) 0.179
Only pandemic vaccine 4 / 5 29 (−176; 82) 0.623 −32 (−694; 78) 0.763
Unvaccinated 72 / 64 Ref. Ref.
a Logistic regression model including 2010–2011 seasonal and monovalent A(H1N1)pdm09 influenza vaccination status as a combined variable (unvaccinated,
only seasonal vaccine, only pandemic vaccine, or both vaccines).
b Logistic regression model including 2010–2011 seasonal and monovalent A(H1N1)pdm09 influenza vaccination status as a combined variable (unvaccinated,
only seasonal vaccine, only pandemic vaccine, or both vaccines) and adjusted for sex, age, major chronic conditions, outpatient visits in the previous year,
swabbing within 4 days of symptom onset, health care setting and period.
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effectiveness [14].
This case–control analysis included only laboratory-
confirmed cases and compared them with test-negative
controls recruited in the same health care settings before
either patient or physician knew the laboratory result, a
fact that provides better comparability between cases
and controls and reduces selection bias [6]. This type of
design has been used in other studies that have evalu-
ated influenza vaccine effectiveness [10-14]. The case–
control study was nested in a population-based cohort
for which extensive and reliable databases are available,
and which is treated by sentinel physicians trained to
detect and swab ILI patients, all of which helps to
prevent unmeasured confounding [22]. All the analyses
were adjusted for the effect of the most commonly
recognized confounding factors.Conclusion
These results support a moderate protective effect of the
2010–2011 seasonal vaccine and do not rule out a possible
low residual effect of the monovalent pandemic vaccine
against influenza in the 2010–2011 season. Our findings
can be added to those of other studies that highlightthe importance of annual immunization of high-risk
populations against influenza, complemented with
other preventive initiatives such as promotion of basic
hygiene measures and avoiding contact with influenza
cases.
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